Detailed Coverage

Parmax Pharma Ltd: Independent Directors Review Open Offer

Parmax Pharma Ltd announced that its Committee of Independent Directors (IDC) has reviewed the open offer made by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with persons acting in concert (PACs). The IDC has recommended on the offer price.

What just happened

The IDC of Parmax Pharma Ltd met on July 25, 2026, to evaluate the open offer from Dhiren Chandulal Shah and Sunil Chinubhai Shah. They are looking to acquire 23,46,250 shares, representing 26.00% of the company's expanded voting share capital, at ₹42.80 per share.

Why this matters

This recommendation is a key step in the open offer process, providing public shareholders with an independent assessment of the offer's fairness. It helps investors decide whether to tender their shares.

The backstory

The open offer is being made by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with PACs, to acquire a significant stake in Parmax Pharma Ltd.

What changes now

Shareholders now have the independent directors' analysis of the offer price, which can influence their participation in the open offer.

Risks to watch

Shareholders should carefully consider the terms of the open offer and the IDC's findings before making a decision. The price is compared against historical transactions and market data.

Peer comparison

No direct peer comparison is available in this filing.

Context metrics (time-bound)

• Open Offer Price: ₹42.80 per share
• Negotiated Price (SPA): ₹35.00 per share
• Negotiated Price (Preferential Issue): ₹36.50 per share
• VWAP (52 weeks preceding PA): ₹31.00 per share
• Highest Price Paid (52 weeks preceding PA): ₹31.00 per share
• 60-day VWAP (BSE): ₹42.79 per share

Reader Takeaway: Independent directors deem offer price fair, exceeding negotiated and market values, guiding shareholder action.